全文获取类型
收费全文 | 390篇 |
免费 | 16篇 |
国内免费 | 14篇 |
专业分类
儿科学 | 15篇 |
妇产科学 | 7篇 |
基础医学 | 31篇 |
口腔科学 | 9篇 |
临床医学 | 23篇 |
内科学 | 89篇 |
皮肤病学 | 5篇 |
神经病学 | 4篇 |
特种医学 | 126篇 |
外科学 | 14篇 |
综合类 | 7篇 |
预防医学 | 7篇 |
眼科学 | 62篇 |
药学 | 13篇 |
肿瘤学 | 8篇 |
出版年
2019年 | 1篇 |
2018年 | 1篇 |
2017年 | 1篇 |
2016年 | 1篇 |
2015年 | 6篇 |
2014年 | 4篇 |
2013年 | 6篇 |
2012年 | 3篇 |
2011年 | 6篇 |
2010年 | 5篇 |
2009年 | 14篇 |
2008年 | 7篇 |
2007年 | 13篇 |
2006年 | 8篇 |
2005年 | 18篇 |
2004年 | 19篇 |
2003年 | 17篇 |
2002年 | 3篇 |
2001年 | 4篇 |
2000年 | 4篇 |
1999年 | 7篇 |
1998年 | 19篇 |
1997年 | 23篇 |
1996年 | 22篇 |
1995年 | 10篇 |
1994年 | 16篇 |
1993年 | 7篇 |
1992年 | 6篇 |
1991年 | 1篇 |
1990年 | 6篇 |
1989年 | 11篇 |
1988年 | 9篇 |
1987年 | 10篇 |
1986年 | 10篇 |
1985年 | 14篇 |
1984年 | 5篇 |
1983年 | 17篇 |
1982年 | 17篇 |
1981年 | 15篇 |
1980年 | 10篇 |
1979年 | 3篇 |
1978年 | 6篇 |
1977年 | 11篇 |
1976年 | 9篇 |
1975年 | 2篇 |
1973年 | 2篇 |
1972年 | 2篇 |
1971年 | 7篇 |
1970年 | 2篇 |
排序方式: 共有420条查询结果,搜索用时 15 毫秒
1.
2.
3.
Perfluorochemicals as US contrast agents for tumor imaging and hepatosplenography: preliminary clinical results 总被引:3,自引:0,他引:3
Mattrey RF; Strich G; Shelton RE; Gosink BB; Leopold GR; Lee T; Forsythe J 《Radiology》1987,163(2):339-343
In animals, perfluorochemicals (PFCs) are effective ultrasound (US) contrast agents that produce hepatic, splenic, and tumor enhancement. The use of Fluosol-DA 20%, an emulsion of perfluorodecalin and perfluorotripropylamine, was studied in nine non-critically ill patients with cancer who had liver lesions. US studies without Fluosol were compared with studies obtained 24, 48, and 72 hours after Fluosol infusion. Vital signs and extensive laboratory analyses are performed before and after Fluosol infusion. Liver metastases from colonic, pancreatic, and gastric carcinoma exhibited rim or diffuse enhancement after a Fluosol dose of 1.6 g/kg or greater. Fluosol produced echogenic enhancement of the liver and spleen relative to kidney at a dose of 2.4 g/kg, allowing the detection of nonenhancing lesions. In addition, Fluosol at a dose of 1.6 g/kg or greater allowed detection of lesions not seen before contrast medium was administered in three of the seven patients studied. There was a mild increase in the level of serum glutamic oxaloacetic transaminase in two patients, one given 2.4 and the other 3.2 g/kg of Fluosol. Mild and transient allergic reactions without change in vital signs were experienced by two patients. 相似文献
4.
5.
6.
Dohle GR; Ramos L; Pieters MH; Braat DD; Weber RF 《Human reproduction (Oxford, England)》1998,13(3):620-623
Male genital tract obstructions may result from infections, previous
inguinal and scrotal surgery (vasectomy) and congenital bilateral absence
of the vas deferens (CBAVD). Microsurgery can sometimes be successful in
treating the obstruction. In other cases and in cases of failed surgical
intervention, the patient can be treated by microsurgical or percutaneous
epididymal sperm aspiration (MESA, PESA) or testicular sperm extraction
(TESE) and intracytoplasmic sperm injection (ICSI). We present the results
of 39 ICSI procedures for obstructive azoospermia in 24 couples. The
aetiology of the obstruction was failed microsurgery in 11 patients, CBAVD
in nine and genital infections in four. Sperm retrieval was accomplished
via MESA in four cases, PESA in 18 cases and via TESE in 11 cases. TESE was
only applied when PESA failed to produce enough spermatozoa for
simultaneous ICSI. In six patients, the ICSI procedure was performed with
cryopreserved spermatozoa after an initial PESA procedure. Fertilization
occurred in 47% of the metaphase II oocytes; embryo transfer was performed
in 92% of procedures and resulted in a clinical pregnancy in 13/39
procedures. Ongoing pregnancy was achieved in 10/39 procedures. One
pregnancy was terminated early after prenatal investigation showed a
cytogenetic abnormality (47,XX+18, Edwards syndrome). The other nine
pregnancies resulted in the live birth of 10 children, without any
congenital abnormalities. Epididymal and testicular retrieved spermatozoa
were successfully used for ICSI to treat obstructive azoospermia, and
resulted in an ongoing pregnancy in 10 of 24 couples (41.6%) after 39 ICSI
procedures, a success rate of 25.6% per treatment cycle and of 27.7% per
embryo transfer.
相似文献
7.
8.
L1 knockout mice show dilated ventricles, vermis hypoplasia and impaired exploration patterns 总被引:8,自引:3,他引:8
Fransen E; D'Hooge R; Van Camp G; Verhoye M; Sijbers J; Reyniers E; Soriano P; Kamiguchi H; Willemsen R; Koekkoek SK; De Zeeuw CI; De Deyn PP; Van der Linden A; Lemmon V; Kooy RF; Willems PJ 《Human molecular genetics》1998,7(6):999-1009
L1 is a neural cell adhesion molecule mainly involved in axon guidance and
neuronal migration during brain development. Mutations in the human L1 gene
give rise to a complex clinical picture, with mental retardation,
neurologic abnormalities and a variable degree of hydrocephalus. Recently,
a transgenic mouse model with a targeted null mutation in the L1 gene was
generated. These knockout (KO) mice show hypoplasia of the corticospinal
tract. Here we have performed further studies of these KO mice including
magnetic resonance imaging of the brain, neuropathological analysis and
behavioral testing. The ventricular system was shown to be abnormal with
dilatation of the lateral ventricles and the 4th ventricle, and an altered
shape of the Sylvius aqueduct. Additionally, the cerebellar vermis of the
KO mice is hypoplastic. Their exploratory behavior is characterized by
stereotype peripheral circling reminiscent of that of rodents with induced
cerebellar lesions.
相似文献
9.
目的: 研究1,25-二羟维生素D3 对结肠癌细胞系Caco-2 细胞中报告基因表达的作用,并探讨在报告载体pGL2 序列中存在潜在的抑制性维生素D应答元件(VDRE)的可能性。方法: 采用磷酸钙沉淀法将报告载体转染入Caco-2 细胞。Caco-2细胞经不同浓度1,25-二羟维生素D3 处理后测定细胞裂解液中表达的荧光素酶活性。结果: 应用pGL2 报告载体时,当用pSG5-VDR表达载体共转染后,1,25-二羟维生素D3显著地抑制Caco-2 细胞荧光素酶的表达(P< 0.05);而未使用该表达载体共转染则无抑制作用(P> 0.05)。应用pGL3 报告载体时,不同浓度的1,25-二羟维生素D3 对pLG3转染后Caco-2 细胞表达的荧光素酶活性均无显著抑制作用(P> 0.05),该作用不依赖是否存在有pSG5-VDR表达载体共转染。结论:1,25-二羟维生素D3 对报告载体PGL2 荧光素酶表达具有抑制作用,而对pGL3 则否;类似人类PTH基因中的潜在抑制性VDRE存在于报告载体pGL2,在pGL3 中该VDRE业已改变。 相似文献
10.
RF Lamont 《BJOG : an international journal of obstetrics and gynaecology》2006,113(S3):96-99
Over the past 15 years, the use of β-agonists has declined worldwide. Following the Royal College of Obstetricians and Gynaecologists guidelines in 2002, clinicians in the UK and beyond were faced with the dilemma of continuing to use β-agonists, desist from using tocolytic therapy completely or choosing to change to atosiban or calcium channel blockers (CCBs). While grade A level 1 evidence exists to show that atosiban is significantly more efficacious than placebo and significantly safer than β-agonists for the treatment of spontaneous preterm labour, the evidence for CCBs, such as nifedipine, is much less robust and no placebo-controlled trials have been performed. Published studies on nifedipine are largely investigator-led studies of small sample size, which lack sufficient power. As a result, most of the evidence has been based on meta-analyses of these studies, which look retrospectively at pooled data and are only as good as the quality of the studies included. In light of this, a tool was developed to produce a systematic review of studies on tocolytic effectiveness, which can and should be applied to all tocolytics and which considered both method- and topic-specific markers of quality. In the process of applying this tool to nifedipine, an extensive literature search identified 31 studies for a systematic review of the quality of nifedipine studies assessed by eight paired reviewers with wide experience in the subject of spontaneous preterm labour and preterm birth. Forty topic- and method-specific items of quality were assessed. The paucity of good quality studies of nifedipine used for the treatment of spontaneous preterm labour should be highlighted in meta-analyses or systematic reviews, which measure efficacy and should limit and influence the degree to which recommendations and guidelines are made on the basis of such studies. 相似文献